← Back to Search

Angiogenesis Inhibitor

Paclitaxel for Fallopian Tube Cancer

Phase 2
Waitlist Available
Led By Anil K. Sood, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 32 weeks
Awards & highlights

Study Summary

This trial looks at the side effects of a chemotherapy combination including paclitaxel and bevacizumab, with or without the addition of emactuzumab. Emactuzumab is an antibody that works to block tumor growth by targeting certain cells. The goal is to see if the addition of emactuzumab to paclitaxel and bevacizumab improves treatment of ovarian, fallopian tube, or primary peritoneal cancer.

Eligible Conditions
  • Fallopian Tube Cancer
  • Fallopian Tube Carcinoma
  • Fallopian Tube Adenocarcinoma
  • Ovarian Carcinoma
  • Endometrioid Adenocarcinoma
  • Peritoneal Serous Adenocarcinoma
  • Ovarian Cancer
  • Ovarian Adenocarcinoma
  • Ovarian Brenner Tumor
  • Peritoneal Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 32 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 32 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Part 1: To Evaluate the Safety of Administration of Paclitaxel, Bevacizumab and Emactuzumab Over 4 Weeks.
Part 2B: To Compare the Progression-free Survival (PFS) of Patients With Stable Disease Following Part 2A Randomized to Paclitaxel Plus Bevacizumab or to Paclitaxel, Bevacizumab Plus Emactuzumab.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm II (paclitaxel, bevacizumab, emactuzumab)Experimental Treatment5 Interventions
Patients receive paclitaxel and bevacizumab as in Arm I. Patients also receive emactuzumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group II: Arm I (paclitaxel, bevacizumab)Active Control3 Interventions
Patients receive paclitaxel IV over 60 minutes on days 1, 8, 15, and 22 and bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bevacizumab
2013
Completed Phase 4
~5280
Emactuzumab
2015
Completed Phase 1
~260
Paclitaxel
2011
Completed Phase 4
~5380

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,657 Previous Clinical Trials
40,933,658 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
2,967 Previous Clinical Trials
1,804,793 Total Patients Enrolled
Anil K. Sood, MDPrincipal InvestigatorM.D. Anderson Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
2017. "Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02923739.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top